Evidence map›Paper›PMID 26617900›Full record

ArticleInternational journal of clinical and experimental pathology2015

Human recombinant-B-type natriuretic peptide protect ventricular function and structure in ST-elevation myocardial infarction.

Xin Gong, Zhengbin Mou, Li Shao, Yong Zou, Youyi Gu, Shaoli Sun

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Xin GongDepartment of Integrated Traditional and Western Medicine, Yuhuangding Hospital Yantai, Shandong, China.
Zhengbin MouDepartment of Oncology, Yuhuangding Hospital Yantai, Shandong, China.
Li ShaoDepartment of Integrated Traditional and Western Medicine, Yuhuangding Hospital Yantai, Shandong, China.
Yong ZouDepartment of Integrated Traditional and Western Medicine, Yuhuangding Hospital Yantai, Shandong, China.
Youyi GuDepartment of Integrated Traditional and Western Medicine, Yuhuangding Hospital Yantai, Shandong, China.
Shaoli SunDepartment of Integrated Traditional and Western Medicine, Yuhuangding Hospital Yantai, Shandong, China.
Yuhuangding Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundST-elevation myocardial infarction (STEMI) is the most serious clinical type of coronary artery disease (CAD), which will lead to a loss of contractile function asa result of adverse left ventricular (LV) remodeling. Post-myocardial infarction remodeling is detrimental to the left ventricular function, which is strongly related to clinical outcome,including heart failure and cardiac death. And our study was designed to assess the efficacy of 72-hour IV infusion of rh-BNP therapy in STEMI patients with or without successful primary PCI, in preventing adverse LV remodeling and preserving LV function.

methods100 patients diagnosed as STEMI combined with acute heart failure (Killip classification ≥ 2) were recorded. And they were divided into "rh-BNP treatment group" (n=50) and "control group" (n=50). In addition to conventional heart failure therapy, patients in the rh-BNP group received rh-BNP infusion for 72 hours. All patients were followed up at 3 month after discharge. Their medical history was taken, as well as the presence or absence of relevant symptoms. 6-minute walking test, as well as echocardiographic indexes were recorded to evaluate the improvement of cardiac function.

resultsThe data analysis about demographic comparison, including those related complicated diseases among groups showed no significant difference. After the follow-up, the indicators were all better than baseline among four subgroups (all P<0.001). Results showed that rh-BNP was able to significantly reduce the NT-pro BNP levels (P<0.001), decrease LVESD (P<0.01), and increase LVEF (P<0.05). The difference of 6WMT between two groups was significant (P<0.001). According to the classification of 6WMT, the multivariate Cox regression showed that the usage of rh-BNP was an independent predictor for 6WMT (OR 0.478, 95% CI, 0.290-0.787), while it may not for MACE (OR 1.762, 95% CI, 0.793-3.913).

conclusionsAlthough the use of rh-BNP was not an independent risk factor in prediction of MACE in our study, the current data still showed that rh-BNP is a useful prognosis factor of 6WMT in the STEMI patients. The protection of ventricular function and structure in STEMI patients is affirmative.

Indexed as

AgedEchocardiographyFemaleHeart FailureHumansMaleMiddle AgedMyocardial InfarctionNatriuretic Peptide, BrainPeptide FragmentsRecombinant ProteinsVentricular FunctionVentricular Function, LeftVentricular RemodelingNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)Recombinant Proteinsacute heart failureHuman recombinant BNPleft ventricular functionST-elevation myocardial infarction

Identifiers

PMID26617900
PMCPMC4637716
OpenAlexW2194567417

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.